TNFRSF4 and neoplasm: In the experiment, the combination of an OX40 agonist with chemotherapeutic agents induces a marked increase in intratumoral NK cell density, augments their IFN-γ production, enhances NK cell antitumor activity, and significantly suppresses tumor growth (76, 77).